C02CA04 Doxazosin
ATC class of level 5 – chemical substance
This page lists the patient medication information or the product monograph for 9 drugs in this drug class.
- 9 prescription (Rx)
Active ingredient: Doxazosin (doxazosin mesylate) – all drugs with this active ingredient, also in combination.
Place in the ATC system
- C Cardiovascular system drugs 1,385 drugs
- C02 Antihypertensives 83 drugs
- C02C Antiadrenergic agents, peripherally acting 12 drugs
- C02CA Alpha-adrenoreceptor antagonists, peripherally acting 12 drugs
- C02CA04 Doxazosin 9 drugs
- C02CA Alpha-adrenoreceptor antagonists, peripherally acting 12 drugs
- C02C Antiadrenergic agents, peripherally acting 12 drugs
- C02 Antihypertensives 83 drugs
Drugs in the class
| Drug | Rx or OTC |
|---|---|
| Apo-Doxazosin PM | prescription (Rx) |
| Cardura-1 Tab 1mg PM | prescription (Rx) |
| Cardura-1,2,and 4 PM | prescription (Rx) |
| Dom-Doxazosin PM | prescription (Rx) |
| Doxazosin-1 PM | prescription (Rx) |
| Jamp-Doxazosin | prescription (Rx) |
| Mylan-Doxazosin PM | prescription (Rx) |
| PMS-Doxazosin PM | prescription (Rx) |
| Teva-Doxazosin PM | prescription (Rx) |
Other classes of the same level
- C02CA01 Prazosin 3 drugs
Other names of the drug class
- Czech: C02CA04 Doxazosin
- English (United Kingdom): C02CA04 doxazosin
- French: C02CA04 doxazosine
- German: C02CA04 Doxazosin
- Spanish: C02CA04 Doxazosina
- German (Austria): C02CA04 Doxazosin
- Italian: C02CA04 DOXAZOSIN
- Polish: C02CA04 Doksazosin
- Turkish: C02CA04 doksazosin
- Portuguese (Brazil): C02CA04 Doxazosina
- Slovak: C02CA04 Doxazosín
- German (Switzerland): C02CA04 Doxazosin
- French (Switzerland): C02CA04 Doxazosine
- Italian (Switzerland): C02CA04 Doxazosin
- Dutch: C02CA04 Doxazosine
Sources
- Patient medication information and product monographs: Health Canada, Drug Product Database
- Active ingredients, ATC codes and Rx or OTC status: Health Canada, Drug Product Database
- World Health Organization (WHO): ATC/DDD system, class C02CA04
Ask your doctor or pharmacist for advice.